Common REMS Drugs

Drug or Class	Safety Concerns
Apixaban	Thrombotic events - stroke, in patients with nonvalvular atrial fibrillation when stopping without introducing an adequate alternative anticoagulant
Ambrisentan	Adverse fetal outcomes
belatacept	Post-transplant lymphoproliferative disorder (PTLD)
Bosentan	Hepatotoxicity, teratogenic effects
Buprenorphine	Abuse potential
Buproprion	Serious risks
Clozapine	Neutropenia, aplastic anemia
Darbepoetin	Cardiovascular events, stroke, increased mortality, tumor progression
Dofetilide	Ventricular Arrhythmia
Dronedarone	Prevent use in symptomatic heart failure and atrial fibrillation
Epoetin alpha	Cardiovascular events, stroke, increased mortality, tumor progression
Fentanyl	Abuse potential
Fingolimid	Bradyarrhythmia and atrioventricular block at treatment initiation, Infections, macular edema, respiratory effects, hepatic effects, and fetal risk
Hydromorphone	Overdose with abuse
Isotretinoin	Teratogenic - iPLEDGE
Letairis	Hepatotoxicity, teratogenic effects
Liraglutide	Medullary thyroid carcinoma and the risk of acute pancreatitis
Metoclopramide	Tardive dyskinesia
Mifepristone	Use in inappropriate clinical situations
Morphine	Abuse potential
Mycophenolate	To avoid in pregnancy
Naltrexone	Use in appropriate clinical situations
Natalizumab	Progressive multifocal leukoencephalopathy (PML) - TOUCH
Olanzapine	Post-injection delirium/ sedation syndrome
Oxycodone	Overdose
Rosiglitazone	Myocardial infarction
Tapentadol	Overdose
Testosterone	Serious risks
Thalidomide	Teratogenic
Tofacitinib	Serious infections
Varenicline	Neuropsychiatric symptoms
Vigabatrin	Irreversible vision loss

Source:

http://dig.pharm.uic.edu/faq/restrictedaccess.aspx

http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm

http://www.ashp.org/REMS